Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Curasan AG    CURK   DE000A2YPGM4

CURASAN AG

(CURK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

curasan AG: curasan AG and Donau Invest, Vienna, agree on a restructuring concept by an insolvency plan

06/25/2020 | 01:40pm EST

DGAP-Ad-hoc: curasan AG / Key word(s): Miscellaneous
curasan AG: curasan AG and Donau Invest, Vienna, agree on a restructuring concept by an insolvency plan

25-Jun-2020 / 19:37 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


curasan AG: curasan AG and Donau Invest, Vienna, agree on a restructuring concept by an insolvency plan

Kleinostheim, Germany, 25 June 2020 - In the ongoing insolvency proceedings, curasan AG (shares: ISIN DE000A2YPGM4 / convertible bond: ISIN DE000A2TR497) today concluded a binding investment agreement with Donau Invest Beteiligungs Ges. m.b.H., Vienna, for the financial restructuring of the company within the framework of an insolvency plan.

The signing of the investment agreement and the binding key points paper for the insolvency plan in the curasan AG proceedings took place with the consent of the creditors' committee and the insolvency administrator, lawyer Frank Schmitt.

In implementation of this agreement, an insolvency plan will be submitted to curasan AG's creditors for approval as soon as possible. This plan provides that Donau Invest will make the necessary amounts available to curasan AG until curasan AG is sustainably financially restructured. The creditors of curasan AG, who are to waive part of their claims, will be satisfied from a further amount made available by Donau Invest at a quota the exact amount of which will also depend on the development of the operating business in the coming weeks. The restructuring concept currently already being implemented will be further implemented in the interest of the company's creditors. The corresponding creditors' meeting will probably vote on the insolvency plan to be presented at a voting and discussion meeting in the course of the third quarter of 2020. From today's perspective, approval of the plan can be expected.

In order to ensure the continued existence of curasan AG until the insolvency plan is confirmed, Donau Invest has committed itself to make the necessary liquidity available to the company by means of a so-called mass loan.

The transaction is subject to customary market conditions, such as antitrust approvals.

A further essential component of the insolvency plan for curasan AG to be submitted to the creditors is to be a capital reduction to probably zero euros and a subsequent cash capital increase. In a first step, the new shares are to be fully subscribed by Donau Invest. The existing shareholders will not be allowed to participate in this capital measure. They will not be granted a right to subscribe for new shares. This is the only way to achieve a thorough restructuring of curasan AG. The legal admissibility of such a procedure has been confirmed by the competent courts, among others in the insolvency proceedings of Pfleiderer AG and IVG AG, which have also been restructured by means of an insolvency plan. Both plans were implemented in this way. As a result of these measures, the existing shareholders are to leave the company. Under the insolvency plan, curasan AG should be delisted and continue to exist as an unlisted company.

Management Board

---- End of the ad hoc release ----


Contact curasan AG:
Andrea Weidner
Investor Relations &
Corporate Communications
+49 6027 40 900-51
ir@curasan.com


25-Jun-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: curasan AG
Lindigstraße 4
63801 Kleinostheim
Germany
Phone: 06027/40 900 0
Fax: 06027/40 900 29
E-mail: info@curasan.de
Internet: www.curasan.de
ISIN: DE000A2YPGM4
WKN: A2YPGM
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1079489

 
End of Announcement DGAP News Service

1079489  25-Jun-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1079489&application_name=news&site_id=zonebourse

© EQS 2020
All news about CURASAN AG
07/29CURASAN AG : Preliminary announcement of the publication of financial reports ac..
EQ
06/30CURASAN AG : curasan AG postpones annual financial report 2019 to 31 July 2020
EQ
06/29CURASAN AG : Preliminary announcement of the publication of financial reports ac..
EQ
06/25CURASAN AG : curasan AG and Donau Invest, Vienna, agree on a restructuring conce..
EQ
06/17CURASAN AG : Notification of a loss amounting to half of the equity capital in a..
EQ
06/08CURASAN AG : Release according to Article 40, Section 1 of the WpHG [the German ..
EQ
06/03CURASAN AG : Opening of insolvency proceedings on the assets of curasan AG
EQ
05/25CURASAN AG : EBITDA 2019 probably better than results forecast
EQ
04/28CURASAN AG : Preliminary announcement of the publication of financial reports ac..
EQ
04/15CURASAN : postpones publication of FY results 2019
PU
More news
Financials
Sales 2019 6,20 M 7,38 M 7,38 M
Net income 2019 -4,68 M -5,57 M -5,57 M
Net Debt 2019 1,19 M 1,42 M 1,42 M
P/E ratio 2019 -1,84x
Yield 2019 -
Capitalization 1,18 M 1,40 M 1,40 M
EV / Sales 2018 1,59x
EV / Sales 2019 1,58x
Nbr of Employees -
Free-Float -
Chart CURASAN AG
Duration : Period :
curasan AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 0,13 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Torben Sorensen Chief Executive Officer
Detlef Wilke Chairman-Supervisory Board
Fabian Peters Technical Director
Christine Böhm Chief Medical Officer
Isabella de Krassny Member-Supervisory Board